HIV VACCINE PRODUCTION
$463,287N01FY2000AINIH
Novartis Vaccines And Diagnostics, Inc., Cambridge MA
Investigators
Linked publications & trials
Paper 21894641Paper 21105782Paper 18243435Paper 18061231Paper 17707956Paper 17067273Paper 17038830Paper 16920175Paper 16527321Paper 16275150Paper 15285704Paper 14512572Paper 12551968
Abstract
The objective of this contract is to produce, scale-up, characterize and formulate reagent grade (GLP) and /or clinical grade (cGMP) HIV-1recombinant whole-killed vaccine products for animal and/or human trials. For clinical grade materials the manufacturer must perform all required vaccine lot characterization tests. The contractor must also work together with other contractors performing safety and immunogenicity testing of the vaccine product or producing FDA-required documentation in support of an IND.
View original record on NIH RePORTER →